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OBJECTIVES: The impact of new oncology therapies on OS is often assessed by
comparing median OS times in randomised controlled trials. Although this data is
usually available even when many patients remain alive at the end of the trial, the
survival times of those surviving beyond the median point may not be adequately
accounted for in this comparison. In this case study, we discuss the median and the
mean OS using data from a recently published randomised trial. METHODS: Me-
dian OS in the ipilimumab-alone (IPI) and gp100 alone-arms of the trial of IPI in
pre-treated metastatic melanoma (MM) patients (Hodi et al., 2010, NEJM) was com-
pared with non-parametric estimates of mean survival (area under digitised Ka-
plan-Meier survivor function) over four years (maximum follow up 55 months). We
reviewed the methods literature and approaches adopted in relevant assessments.
RESULTS: In this case study, for MM population followed over four years median OS
was reached in the control arm at 6.4 months, and at 10.1 months in the IPI alone
arm, a difference in medians of 3.7 months. Mean OS (area under the curve) over 4
years was 11.5 months in the control arm and 17.6 months in the IPI alone arm, a
difference for IPI of 6.1 months. Though larger than the difference in median OS,
this represents a lower bound on the mean OS benefit over the remaining lifetime,
since the survival benefit was truncated at the end of the trial. CONCLUSIONS:
Mean and median OS both have a place in characterizing OS. In this case study, it
would appear that mean OS may be more informative in describing the potential
benefit of the treatment in patients with MM. Health care decision makers should
consider all the available data when assessing the potential benefits offered by new
therapies in oncology.
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OBJECTIVES: Emerging developments in nanomedicine allow the development
of genome-based technologies for unobtrusive and individualized screening of
colorectal cancer. An example is the nanopill that is currently being developed.
The pill collects gastrointestinal fluid and screens DNA for tumour markers. The
main objective is to inform further development by determining the public
preferences for screening as well as the possible uptake of the nanopill com-
pared to standard CRC screening. METHODS: Data was collected through a dis-
crete choice experiment among individuals aged between 50 and 74 years living in
the The Netherlands and the UK. A full-profile fractional factorial design with a
balanced overlap was implemented. Fourteen random and two fixed choice-tasks
with triplets and dual-none response were used. Through an extensive literature
search following attributes were included: preparation, technique, sensitivity,
specificity, complication rate, and testing frequency. Data were analysed using
Hierarchical Bayes analysis and a Multinomial Logit model. RESULTS: Thirteen
hundred fifty-six respondents completed the questionnaire, from which 884 (65%)
passed the consistency test. Most preferred attributes were: technique (pill), prep-
aration (none); sensitivity (100%), specificity (100%), complications (none), and in-
terval (every 5 years). Nanopill was the most preferred screening modality (46%),
followed by iFOBT (40%), colonoscopy (2%), and sigmoidoscopy (1%). Eleven percent
would choose not to be screened. CONCLUSIONS: CRC screening has been imple-
mented in a number of countries using standard screening techniques, like FOBT
and virtual colonoscopy. However, current developments in nanomedicine allow
the development of new technologies for individualized screening. The expected
benefits delivered by the nanopill are an improved screening adherence, earlier
diagnosis and an increased test performance. The present study suggests the
nanopill to be accepted by the public, which does support further development.
However, the study used hypothetical scenarios to describe the nanopill and the
results do not guarantee market uptake. Cost-benefit analysis and clinical trials
remain mandatory.
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OBJECTIVES: Our aims were to investigate the association between baseline
health-related quality of life (HRQOL) scores of the EORTC QLQ-C30 and survival.
METHODS: We analyzed data from pooled, randomized, controlled trials from Na-
tional Cancer Institute Canada Clinical Trials Group started between 1991 and 2004,
which included survival data from 3635 patients with 8 different cancer sites. So-
ciodemographic variables were sex (men vs. women) and age ( 60 vs.  60), and
clinical variables were WHO performance status (0-1 vs. 2-3) and distant metasta-
ses (no vs. yes). The prognostic significance of sociodemographic and clinical vari-
ables and the 15 QLQ-C30 scales were assessed with Cox proportional hazard mod-
els stratified for cancer site. RESULTS: In the stratified multivariate model
including sociodemographic, clinical, and HRQOL data, the HRQOL parameters of
global QOL/health status (hazard ratio [HR] 1.097, 95% CI 1.05- 1.14; p.0001), phys-
ical function (0.94, 0.897-0.98; p0.0010), dyspnoea (1.04, 1.00-1.07; p0.0120), and
appetite loss (1.06, 1.03-1.09; p.0001) provided significant prognostic information
in addition to the sociodemographic and clinical variables. The gain in predictive
accuracy of prognosis of overall survival of the four HRQOL parameters over the
sociodemographic and clinical characteristics was 3% (Harrell’s C-index for so-
ciodemographic and clinical variables  0.69, and for sociodemographic, clinical,
and HRQOL variables 0.71). The model developed by Quinten et al. 2009 included
pain but this was not found to be statistically significant in our model.
CONCLUSIONS: Our findings suggest that HRQOL scales of the EORTC QLQ-C30
provide prognostic information in addition to that of sociodemographic and clini-
cal measures. This replicates previous findings (Quinten et al., 2009) showing that
HRQOL data can help to predict survival in patients with cancer, although the
specific HRQOL domains that are predictive may vary. The impact of these findings
for clinical management (e.g., in stratification for clinical trials entry or treatment
decision making) need additional study.
CN4
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OBJECTIVES: Hepatocellular carcinoma (HCC) is both common and deadly; yet
predicting the future impact of technologies is difficult. We studied opinions about
the potential impact of HCC-control technologies over a 5-10 year horizon and
compared results from Europe and Asia. METHODS: Clinical, policy and patient
advocacy stakeholders were purposively sampled equally from Asia and Europe.
Opinions about eleven possible technologies were studied using best-worst scal-
ing. Here a balanced incomplete block design (BIBD) generated 11 choice tasks
presenting respondents with subsets of five technologies and asking them to as-
sess which might have the most and least impact on HCC control. Assuming se-
quential best-worst choice, respondents’ choices were analyzed using a stratified
conditional logistic regression. Heterogeneity was examined by assessing ordinal
and cardinal properties using Spearman’s Rho and Wald test respectively.
RESULTS: A total of 160 stakeholders (response rate: 46%) completed the survey
and self-identified as having local/regional (30%), national (46%) or international
(24%) influence. Overall, respondents saw molecular targeted therapy (p 0.001)
and early detection (p 0.001) as having most potential, while surgical techniques
(p 0.001) and biopsy-free diagnosis (p 0.001) were viewed negatively. While the
ordinal rankings of technologies were similar (Spearman’s Rho0.81, P0.003),
significant differences were found for some technologies across regions – e.g. in-
terventional radiology was positively valued in Europe (P0.002), but viewed neg-
atively in Asia (P0.118), but adjuvant/neo-adjuvant therapy was viewed positively
in Asia (P0.001), but negatively in Europe (P0.001). CONCLUSIONS: While best-
worst scaling methods are likely to have an important role in informing horizon
scanning and other aspects of health technology assessment, issues of regional
heterogeneity are important to explore. Our results indicated that heterogeneity
may be more important when considering the cardinal values placed on the ele-
ments being examined, as opposed to the ordinal rankings; heterogeneity was not
found for either the best or worst technologies.
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OBJECTIVES: Within cost effectiveness analysis, joint uncertainty in costs and
effects is commonly dealt with using probabilistic sensitivity analysis (PSA). Al-
though economic models using patient level data can simulate more complex
disease processes than cohort-based models, the computational time required to
eliminate 1st-order uncertainty often makes extensive PSA impossible. To over-
come this, a non-parametric artificial neural network (ANN) simulation meta-mod-
elling method is presented using a case study that evaluates the cost-effectiveness
of intensive blood-glucose monitoring in patients with type 2 diabetes. METHODS:
A234 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
A complex individual patient simulation model (UKPDS Outcome Model version
1.3) was used with quality adjusted life years (QALY) and cost of complications as
model outputs. To reduce 1st-order uncertainty, 1000 patients were simulated for
each input combination selected. ANN simulation meta-models using a sample of
200 individual runs were developed and cross-validated to approximate the origi-
nal simulation as these do not require any specific input-output functional rela-
tionship and can handle any number of input parameters. Performance was com-
pared with a Gaussian Process (GP) meta-model, and a valid and better predictive
meta-model was then used for PSA. RESULTS: From ANN meta-models, the mean
absolute percentage error (defined as positive difference between the predicted
and true output divided by the range in true output) was 3.8 % for costs and 1.4% for
QALYs compared with 5.1% and 2.1% in GP meta-models. The distribution of errors
was approximately symmetrical around zero meaning that mean costs and QALYs
for an intervention are unlikely to be affected by the small inaccuracies associated
with ANN approximations. CONCLUSIONS: ANN produces better predictive capa-
bility than GP meta-models in estimating costs and QALYs from the UKPDS out-
come model. A PSA carried out using the ANN meta-model demonstrated the po-
tential for ANN in analysing complex health economic models.
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OBJECTIVES:Different methods of meta-analysis on model parameters can lead to
different outcomes of cost-effectiveness (CE) modeling. As the “true” CE is un-
known, it is unclear which method performs best. We compared different methods
of meta-analysis with regards to the underlying “true” CE outcome. METHODS: In
a simulation study we constructed two patient populations and their treatments
(“truth”): a chronic disease with events and a progressive lethal disease. We drew
trials from these populations, comparing two treatments, varying the number of
trials, trial sizes and between-study heterogeneity in scenarios. From each trial
utilities, transition and event probabilities, risk-differences and log-risk-ratios
were estimated. These parameters were synthesized using frequentist fixed-ef-
fects (FFE) and random-effects (FRE), Bayesian fixed-effects (BFE) and random-ef-
fects (BRE) models. A CE model was filled and probabilistic sensitivity analysis was
performed. We repeated this trial sampling, leading to 1000 sets of health economic
outcomes for each scenario. We compared methods of meta-analysis on bias and
coverage, the percentage of draws that the “true” outcome lies in the confidence
interval. RESULTS: Even in the most heterogeneous scenario, biases were limited
to approximately 5%, and similar for all methods, but small biases in individual
treatment arms occasionally led to biases up to 30% in the difference between
arms. FFE models consistently have lower coverage than BFE. With homogeneous
trials, all methods have coverage above 80% for all outcomes. BRE has coverage
higher than 99% for all outcomes, regardless of heterogeneity. With heterogeneity,
RE methods perform better than FE and FRE has a lower coverage compared to BRE.
All methods, even with heterogeneous trials, have 100% coverage around the ICER.
CONCLUSIONS: BFE or BRE models are preferred in all situations, as they are more
conservative. However, insight in the real level of heterogeneity is important, as
using BRE without heterogeneity will overestimate uncertainty.
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OBJECTIVES: To develop a method which increases the potential to find statisti-
cally significant differences in costs and effects when a trial is powered using a
dichotomous outcome. METHODS: An example is used of a trial assessing an in-
tervention to prevent late pain. Treatment is expected to increase the percentage of
pain-free patients from 85% to 92%, giving a power of 80% with 500 patients. Using
EQ-5D as outcome decreases the power to 40%. We improve on this by deriving
T-tests in which the following assumptions are taken into consideration: 1. quality
of life with pain (8% vs 15%) is identical in both arms 2. quality of life without pain
(85% vs 92%) is identical in both arms Alternatively, we use a Bayesian approach
assuming that the differences between arms follow normal distributions with
mean zero and varying precision. Using simulations the frequentist and Bayesian
approach are linked and it is analysed to what extent the results depend on the
base line probabilities. RESULTS:Making both assumptions increases the power to
80% as in the binary assessment. Applying assumption 1 increases the power with
only 2%, applying assumption 2 increases it to almost 80%. When assuming that
the outcome is 44% versus 56% instead of 85% vs 92% both assumptions contribute
to the power approximately equally. The Bayesian model coincides with the as-
sumptions from the frequentist approach when the precision is set to the extremes
(zero or infinity). Between these it offers a flexible approach where the road from
one extreme to another is defined by cumulative normal distributions on the log of
the squared root of the precision. CONCLUSIONS: Traditional approaches may
disregard common sense. Building this into the analysis and the assessment of the
data will decrease suggested uncertainty and may decrease the need for large
patients numbers.
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OBJECTIVES: The use of registry databases and indirect comparisons has be-
come important in health economic evaluations. Lack of randomization could
lead to selection bias due to pretreatment differences between patients. To
control for selection bias, the propensity score method (PS) (Rosenbaum & Ru-
bin, 1983) is often applied. However, average treatment effects can vary within
different subgroups. It is yet unclear how to perform subgroups analyses when
the propensity score method is applied. METHODS: A Monte Carlo simulation is
conducted to test the performance of eight different forms of the PS in subgroup
analyses. The PSs differ in whether the variables included in the PS were indicators
of the subgroup and were related to treatment assignment, to outcome or related to
both assignment and outcome. Furthermore the PS is estimated in two ways, pri-
mary on treatment assignment only and secondly on a combination of the treat-
ment assignment and subgroup variable. These PSs were used as adjustment in a
regression model. Simulations are accomplished for 18 different settings varying
sample size, correlation between independent variables and correlation between
independent variables and subgroups. RESULTS: The PS without inclusion of the
variable for subgroups, but with inclusion of variables related to outcome, is the
most appropriate. The PS should be included as a covariate in a regression model
together with the variable for subgroups as covariate, where the PS is based on
treatment assignment only. Larger sample sizes gave less biased results, while a
higher correlation between the independent variables resulted in more biased es-
timates of the treatment and subgroup effect. Correlation between the indepen-
dent variables and the subgroup variable did not lead to biased results.
CONCLUSIONS: The results show the feasibility and validity of the PS in subgroups
analyses when analyzing registry databases and indirect comparisons in economic
evaluations.
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OBJECTIVES:Mood disorders are associated with a high societal cost, mainly due to
productivity loss and in particular presenteeism. The latter should therefore be
measured with the most appropriate tool. The objective is to review the use of ten
instruments in mood disorders and to provide recommendations about the most
appropriate instruments according to the situation. METHODS: A systematic re-
view was conducted using PubMed focusing on ten instruments: Endicott Work
Productivity Scale (EWPS), Health & Labour Questionnaire (HLQ), WHO Health and
Work Performance Questionnaire (HPQ), Health and Work Questionnaire (HWQ),
Lam Employment Absence and Productivity Scale (LEAPS), Sheehan Disability Scale
(SDS), Stanford Presenteeism Scale (SPS), Work and Health Interview (WHI), Work
Limitation Questionnaire (WLQ) and Work Productivity and Activity Impairment
(WPAI). Study characteristics and major results (by symptom level, by treatment
arm, correlation to other scales and use of monetisation) were extracted. RESULTS:
Twenty-nine studies (21 observational studies) were identified. No studies in mood
disorders were retrieved for two scales (HLQ and HWQ). SDS, WLQ and HPQ were
the most commonly used instruments. Most scales demonstrated higher presen-
teeism in patients with symptoms of mood disorders than in patients without.
LEAPS, SDS and WLQ showed increased presenteeism with increasing severity of
disease. Few studies reported results on presenteeism by treatment and no be-
tweentreatment differences were generally observed. Good correlations between
presenteeism instruments and clinical or quality of life scales were reported. Only
three studies converted results from presenteeism scales into monetary units.
CONCLUSIONS: Limited evidence exists to compare the performance of presentee-
ism scales in mood disorders. Recommendations for inclusion of a presenteeism
tool should be driven by theoretical arguments (ease of administration, amenabil-
ity to monetisation) and the study type. Future research should focus on the re-
sponsiveness demonstration and the evaluation of the impact of mood disorders
on self-reported assessment.
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OBJECTIVES: Many health economists consider applying the friction cost method
to estimate the productivity costs, but lack practical data and tools to apply the
method. This study aims to provide estimates for length of the friction period, cost
per working hour/day lost and friction costs for several European countries.
METHODS: Using national aggregate stock and flow time series data on vacancies,
we; 1) estimate vacancy durations for several European countries in order to esti-
mate the length of friction period, and 2) examine estimated vacancy durations
with unemployment and vacancy rates using regression analysis in order to check
the validity of estimated durations. Data for the price component for each country
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